Welcome to our dedicated page for ZEO ScientifiX news (Ticker: zeox), a resource for investors and traders seeking the latest updates and insights on ZEO ScientifiX stock.
ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage biopharmaceutical innovator advancing biologic therapeutics for regenerative medicine and medical aesthetics. This page provides authorized news updates on clinical developments, regulatory milestones, and strategic initiatives directly from the company and verified sources.
Investors and researchers will find timely updates on Zofin™ clinical trials, PPX™ product advancements, and partnership developments with industry leaders like Exotropin. Our curated news feed covers FDA submissions, research breakthroughs, and educational initiatives for healthcare professionals.
Key updates include progress in allogenic/autologous therapy research, cGMP facility expansions, and peer-reviewed study results. Bookmark this page for consolidated access to earnings reports, management commentary, and scientific presentations – all essential for understanding ZEOX's position in regenerative medicine.
For stakeholders tracking biologic therapeutic innovation, this resource offers verified updates without promotional content. Return regularly for the latest developments in extracellular vesicle research and ZEO ScientifiX's contributions to addressing chronic diseases through advanced biologic solutions.
ZEO ScientifiX (OTCQB:ZEOX) has appointed Dr. Peter A. M. Everts as Chief Scientific and Technology Officer. Dr. Everts brings over 35 years of experience as a clinician, researcher, and executive, specializing in medical devices and biological therapies.
Prior to joining ZEO, he served as Chief Scientific Officer at EmCyte and Educational Program Director at Gulf Coast Biologics. He co-founded the Da Vinci Clinic in the Netherlands in 2010 and held senior leadership roles at Avance Medical. Dr. Everts earned his Ph.D. from the University of Utrecht and holds professorships at the University of Queensland and Max Planck University.
The appointment aims to accelerate innovation in biological therapeutics for regenerative medicine and advance the company's clinical trial portfolio. Ian Bothwell, Interim CEO and CFO, emphasized that this strategic addition reinforces ZEO's market position in the biologic medicine industry.
ZEO ScientifiX (OTCQB:ZEOX) has provided a comprehensive business update highlighting several key achievements and future plans. The company successfully completed Phase I clinical trials for its flagship product Zofin™ and is now positioned to pursue Phase II trials targeting multiple indications.
Notable developments include significant growth in sales of their PPX™ product, with revenue increasing by approximately $474,000 for the fiscal year ended October 31, 2024. The company established strategic partnerships with healthcare providers, including Physicians Group, , which operates 75 clinics.
In December 2024, ZEO launched ZEO HAIR GROW™ in collaboration with Exotropin , targeting the hair loss market. The company operates a cGMP FDA compliant research facility and has secured patents for their amniotic fluid product and PPX™ technology. Looking ahead to 2025, ZEO aims to advance clinical trials and is in negotiations for funding to commence Phase II trials as early as Q2 2025.
ZEO ScientifiX (OTCQB:ZEOX) has partnered with affiliate Exotropin to launch ZEO HAIR GROW™, a hair growth solution targeting the 66 million Americans affected by hair loss. The system combines extracellular vesicles from amniotic fluid, adipose stromal cells, and aloe vera plant to optimize scalp health. The product consists of three components: ZEO GROW X™ and ZEO GROW BOOST™ for in-office use, and EXO FOLLICLE FUEL™ for at-home application. The solution will be introduced at the Medical Aesthetics Professionals meeting in Scottsdale, Arizona, November 14-16, 2024.
ZEO ScientifiX (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, has launched a monthly educational series for healthcare providers titled "The Future of Biologic Medicine: Expert-Led Discussions and Case Studies". These events offer insights into regenerative medicine, focusing on extracellular vesicles and autologous biologics, along with practical business solutions for integrating these therapies into medical practices.
The program includes expert-led discussions, tours of ZEO's cGMP-compliant laboratory at Nova Southeastern University, presentations on regulatory aspects, and networking opportunities. ZEO aims to help physicians leverage the clinical potential of biologic therapies and address real-world challenges in incorporating regenerative medicine into their practices.
ZEO recently completed successful Phase 1 clinical trials for its flagship product, Zofin™, and is seeking to launch Phase 2 trials for various indications. The company's goal is to obtain FDA approval for its products in treating various diseases and chronic conditions.
ZEO ScientifiX (OTCQB:ZEOX) has partnered with Physicians Group, , a multi-state provider organization operating 75 clinics with over 750 clinical personnel. This collaboration aims to advance clinical trials for ZEO's products, focusing on health indications commonly seen by Physicians Group's doctors. The partnership provides ZEO with access to a diverse patient population and experienced clinicians for potential trial enrollment.
ZEO recently completed successful Phase 1 trials of its flagship product, Zofin™, and is now preparing for Phase 2 trials for multiple indications. The company's goal is to obtain FDA approval for its products in treating various diseases and chronic conditions. Physicians Group, founded over 25 years ago, has treated more than 150,000 patients and specializes in neck, back, and extremity injuries.
ZEO ScientifiX (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, is advancing its research program into Phase 2 clinical trials. The company recently completed successful Phase 1 trials for its flagship product, Zofin™, and is now seeking FDA approval for various diseases and chronic conditions.
ZEO's product pipeline includes Zofin™, derived from perinatal sources, and Patient Pure X™ (PPX™), an autologous biologic from a patient's peripheral blood. The company is also developing topical aesthetic and anti-aging applications in partnership with Exotropin,
With a projected market growth of 22.8% annually in regenerative medicine, ZEO aims to become an industry leader in biologic therapeutics. The company recently changed its name from Organicell Regenerative Medicine to better reflect its scientific research focus.
